Sovaldi sales drop on Harvoni launch

Executives at Gilead Sciences Inc. (NASDAQ:GILD) on Tuesday were circumspect about forecasting the sales ramp for the company's HCV franchise comprising ultrablockbuster Sovaldi sofosbuvir and its newly lauched Harvoni combo treatment.

On the company's 3Q earnings call, they also avoided making predictions about where HCV drug prices might be headed as Gilead and competitors mount efforts to shorten treatment regimens. ...